STONE, England--(

斯通，英国--(

BUSINESS WIRE

商业热线

)--Instem, a global leader in IT solutions for life sciences, has announced the launch of its new Non-GLP Pathology Module for Provantis, the market share-leading in vivo preclinical study management solution. Trusted by a wide user base including pathologists, Provantis streamlines workflows and enables efficient data management.

)--Instem是生命科学IT解决方案的全球领导者，已宣布推出其针对Provantis的新的非GLP病理学模块，这是市场份额领先的体内临床前研究管理解决方案。Provantis受到包括病理学家在内的广泛用户群的信任，简化了工作流程并实现了高效的数据管理。

This new module is designed to eliminate inefficiencies and modernize pathology workflows. This cloud-hosted solution simplifies data entry, integrates seamlessly with Provantis, and delivers continuous updates for ongoing enhancements..

这个新模块旨在消除效率低下并使病理工作流程现代化。此云托管解决方案简化了数据输入，与Provantis无缝集成，并为正在进行的增强提供了持续更新。。

“This module delivers exactly what our customers have been asking for,” said Beth Hazell, Chief Product Officer at Instem. “It offers significant time savings and improved workflows, providing immediate and long-term value for pathology teams.”

Instem首席产品官贝思·哈泽尔（BethHazell）表示：“这个模块完全满足了我们客户的要求。”。“它大大节省了时间，改进了工作流程，为病理团队提供了即时和长期的价值。”

The Non-GLP Pathology Module allows pathologists to move away from outdated tools like electronic spreadsheets and paper-based systems, improving data accuracy, reducing time to complete tasks, and enhancing cost efficiency. By integrating with Provantis’ ecosystem—supporting protocol definition, necropsy, and reporting—it enables teams to work smarter and faster with minimal disruption..

非GLP病理学模块允许病理学家摆脱电子表格和纸质系统等过时的工具，提高数据准确性，缩短完成任务的时间，提高成本效益。通过与Provantis的生态系统支持协议定义、尸检和报告相结合，它使团队能够以最小的中断更智能、更快地工作。。

“Instem has long been trusted as a leader in GLP preclinical R&D. This is a key step in modernizing non-GLP preclinical workflows and represents the first of many such steps we plan to take in this direction,” said Vik Krishnan, CEO of Instem. “Products like Provantis embody our mission to help researchers Discover new potential treatments, Accelerate their research activities, and ultimately Advance their key R&D programs.”.

Instem首席执行官维克·克里希南（VikKrishnan）表示：“Instem长期以来一直被认为是GLP临床前研发的领导者。这是非GLP临床前工作流程现代化的关键一步，也是我们计划朝着这一方向采取的许多此类步骤中的第一步。”。“像Provantis这样的产品体现了我们的使命，即帮助研究人员发现新的潜在治疗方法，加速他们的研究活动，并最终推进他们的关键研发计划。”。

The module will be available as part of the Provantis platform alongside the existing GLP-compliant Pathology module. For more information, visit

该模块将与现有的符合GLP的病理模块一起作为Provantis平台的一部分提供。有关更多信息，请访问

www.instem.com

www.instem.com

.

.

About Instem

关于Instem

Instem is a leading supplier of SaaS platforms across Discovery, Study Management, Regulatory Submission and Clinical Trial Analytics. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products..

Instem是SaaS平台的领先供应商，涵盖发现、研究管理、监管提交和临床试验分析。Instem应用程序已被全球客户使用，满足了生命科学和医疗保健组织对数据驱动决策的快速扩展需求，从而产生更安全、更有效的产品。。

Founded in the United Kingdom in 1969, Instem has deep roots internationally across North America, EMEA and APAC. Instem maintains a commercial and technical presence throughout these regions and pride ourselves on localized support for our diverse client base. Learn more about Instem here:

Instem于1969年在英国成立，在北美、EMEA和亚太地区都有着深厚的国际渊源。Instem在这些地区保持着商业和技术上的存在，并为我们多样化的客户群提供本地化支持而感到骄傲。在此处了解有关Instem的更多信息：

www.instem.com

www.instem.com

LinkedIn

LinkedIn

X

十